Cardiovascular disease (CVD) ranks among the most common health-related and economic issues worldwide. Dietary factors are important contributors to cardiovascular risk, either directly, or through their effects on other cardiovascular risk factors including hypertension, dyslipidemia and diabetes mellitus. Nutraceuticals are natural nutritional compounds, which have been shown to be efficacious in preventative medicine or in the treatment of disease.
INTRODUCTION
Derivatives of cocoa beans (Theobroma cacao) are widely consumed in cocoa and chocolate (12) . A variety of polyphenols have been identified in cocoa and its derivative. These include catechins, flavonol glycosides, anthocyanins and procyanidins (13) . Cocoa-containing foods provide a higher content of flavonoids per serving than other beverages such as red wine and tea (14) .
The very widespread and frequent consumption of tea makes investigation of its nutraceutical propertied essentials. Polyphenols found in tea include catechins, theaflavins, tannins, and flavonoids. The degree of fermentation of tea leaves influences the chemical composition.
Green tea, which is minimally fermented, contains more catechins such as epigallocatechin gallate, epicatechin-3-gallate, epigallocatechin and epicatechin (15) whereas the more extensively fermented black tea is rich in flavins and thearubigins (16) .
Spirulina
Spirulina is a blue-green microalga (Cyanobacterium). Spirulina is a rich source of protein, vitamins, minerals, carotenoids, and phycocyanins and has a very long history of use as a human foodstuff with no apparent concerns over safety (17, 18) . Table 1 summarizes the methodology and main findings from each study described in the paper.
DYSLIPIDEMIA
Dyslipidemia is an umbrella term for a variety of lipid abnormalities, which increase the risk of cardiovascular disease. Reduction of total cholesterol and low-density lipoproteincholesterol (LDL-C) is effective in the primary and secondary prevention of CVD events (19) .
In particular, low LDL-C levels are associated with lower rates of major coronary events (20) .
Thus nutraceuticals with the potential to modify the plasma lipid profile have the potential to reduce the burden of CVD (21) . Evidence related to the lipid-modifying effects of nutraceuticals is summarized below.
Sterols/stanols
Consumption of plant sterols/stanols has been shown to be associated with lower circulating concentrations of total cholesterol (TC) in humans (22, 23) . Their effect is predominantly LDL-C reduction with little or no effect on high-density lipoprotein cholesterol (HDL-C) or triglycerides (24) . The mechanism by which sterols/stanols reduce LDL-C is associated with a reduction in the intestinal absorption of cholesterol, the upregulation of hepatic LDL receptors (and consequent increased hepatic cholesterol uptake) and reduced production of endogenous cholesterol (25) .
Circulating LDL-C concentrations are inversely correlated with the extent of sterol/stanol consumption. The reduction in plasma LDL-C concentrations associated with sterol/stanol consumption may be as large as 10% (26, 27) . This could lead to reductions in CVD if the effect is associated with a reduction in cardiovascular events similar to that induced by other drugs with similar lipid-lowering efficacy. As sterols/stanols reduce the intestinal absorption of cholesterol, their effect may be additive to that of statins which act by the reduction of hepatic cholesterol production. Importantly, a meta-analysis of 15 randomized controlled trial would appear to suggest that this is the case. It was found that a combination of statins and stanols/sterols lowered the levels of TC and LDL-C to a greater extent than with statins alone.
HDL-C and triglyceride concentrations were not altered by the addition of sterols/stanols to statin therapy (28) . Another meta-analysis demonstrated that the lipid-lowering efficacy of plant sterols/stanols was similar when the sterols were consumed as part of the diet and when they administered as a nutraceutical supplement (26) , thus allowing for flexibility in the method of drug delivery. Some evidence exists regarding the effect of sterol consumption on cardiovascular outcomes.
Observational data suggest that high intake of plant sterols might be associated with MI prevention in men (29) . A recent, large observational study indicated that natural phytosterol intake was associated with TC and LDL-C reduction particularly in men. However, this beneficial effect on lipid profile did not result in a reduction in the risk of CVD (30) . One explanation for the LDL-C reduction failing to translate into a reduction in CVD is that sterols/stanols may reduce the absorption of carotenoids and fat-soluble vitamins (31) . Such an effect would be expected to be associated with a higher incidence of CVD (32) , however further investigations are needed to determine whether this effect occurs in vivo.
Polyphenols
Several studies have indicated that grape polyphenols may influence plasma lipid concentrations. Consumption of grape juice has been associated with elevated HDL-C (33). A study of the effect of polyphenol-rich grape extract supplement (700 mg) on cardiovascular risk in healthy subjects and found that treatment was associated with a reduction in plasma TC and LDL-C concentrations (34) . However, more extensive evidence in the form of a metaanalysis of 9 randomized controlled trials (including 390 participants in total) did not find any effect of grape seed extract on LDL-C (35). While no effect was seen in this combined population, investigations of subpopulations and more sophisticated analysis of lipids has been carried out in other studies. One study found that plasma concentrations of large LDL-C and large LDL particles compared with placebo were decreased in obese subjects supplemented with grape powder for 3 weeks (36) . However, the most atherogenic small LDL particles were not affected by treatment (37) .
Despite, great enthusiasm with respect to the potential health benefits of resveratrol supplementation, a recent meta-analysis did not demonstrate any effect of this compound on plasma levels of TC, LDL-C, triglycerides or glucose. A small reduction in HDL-C concentrations was observed (38) . Larger, well-designed trials are necessary to confirm these outcomes.
The results of studies investigating the effects of cocoa products on lipid profiles have been summarised in a meta-analysis of six randomized controlled trials (39) . The results indicated that short-term cocoa consumption significantly lowered LDL-C by 5.87 mg/dL, marginally lowered TC by 5.82 mg/dL without any evidence of an effect upon HDL-C concentrations.
The effects appeared to be dose-dependent and were observed in the subjects with elevated cardiovascular disease risks but not in healthy participants (39) . A variety of cocoa derivatives exist and do not all necessarily have similar biological effects. Dark chocolate (which contains cocoa butter and cocoa powder) consumption was compared to white chocolate (which contains cocoa butter but not powder) consumption and no difference between the groups was observed in terms of triglyceride, LDL-C and HDL-C in diabetic patients with hypertension (40) . Previous studies have failed to observe benefits of cocoa polyphenols on blood lipids in subjects with hypertension stage 1 (41), overweight (42) Tea polyphenols may also exert lipid-lowering effects. A meta-analysis of 14 randomized controlled trials including 1136 subjects in total found that the administration of green tea beverages or extracts resulted in significant reductions in serum TC and LDL-C concentrations, without altering HDL-C (46) . Another meta-analysis of 20 randomized controlled trials appeared to confirm these results (47) . In another study, both green and black tea and indicated that both reduced LDL-C whereas green tea also reduced TC (48) . Similar properties of black tea were also confirmed by Zhao et al. (49) . These observations highlight one of the difficulties of population research into nutraceuticals: Small differences in the preparation of foods, which are not always captured in food-frequency questionnaires, can result in important differences in the composition of the foods and therefore can result in varying biological effects. Black tea consumption was shown to be more effective in lowering LDL-C in subjects with hypercholesterolemia and other markers of elevated cardiovascular risk (49) . A recent randomized, placebo-controlled trial demonstrated reduced LDL-C and non-HDL-C after long-term supplementation (12 months) with green tea extract in healthy postmenopausal women (50) .
Most studies to date have shown that plasma concentrations of HDL-C in humans are not affected by supplementation with grape products, cocoa and tea polyphenol. The exact mechanisms by green tea exert their LDL-C, lowering effects is not fully understood.
Nevertheless, green tea is easily accessible, popular and safe and it may indirectly lead to lower morbidity and mortality rates due to CVD by improving hyperlipidemia outcomes.
Armolipid Plus is a food supplement combining natural ingredients containing red yeast rice, policosanol, berberine, folic acid, astaxanthin and coenzyme Q10. It has been demonstrated that supplementation with this nutraceutical exert reduction of TC (-19.2%), LDL-C (-17.4%) and triglycerides (-16.3%) (51) . A very recent meta-analysis of several randomized controlled trials revealed that this nutraceutical is safe, well tolerated and confirmed the beneficial effects upon lipid profile with reductions in plasma TC of 11-21% and reductions in LDL-C of 15-31% (52).
Spirulina
Spirulina supplementation has been associated with beneficial alterations to blood lipid profiles (53, 54) . Spirulina maxima, given orally (4.5 g/day, for 6 weeks), was associated with significant changes in TC and LDL-C concentrations (55) . Furthermore, in a population of individuals with dyslipidemia, consumption of 1 g Spirulina per day for 12 weeks decreased mean levels of triglycerides, LDL-C, and TC without any apparent effect on plasma concentrations of HDL-C (56) . A recent meta-analysis of seven randomized controlled trials with Spirulina appeared to confirm these findings (57) . Further well-designed trials are required to clarify the mechanism of action of Spirulina supplementation in dyslipidemia and to determine its effects on cardiovascular outcomes. Table 1 summarizes the methodology and main findings from each study described in the paper.
HYPERTENSION
Hypertension is an important modifiable risk factor for CVD (58) . It has been shown that lowering blood pressure reduces CV risk by 20-25% for myocardial infarction, 35-40% for stroke and about 50% for heart failure (59). The evidence relating to antihypertensive effects of selected nutraceuticals is outlined below.
Sterols/stanols
In contrast to the well-studied effects of sterols and stanols upon lipids, there is a relative paucity of evidence relating to their effects upon blood pressure. Studies have failed to demonstrate antihypertensive effects of sterols/stanols despite continuing treatment for a year or more (60, 61) . One recent study, which aimed to analyse the effect of plant stanol esters on arterial stiffness and endothelial function in adults also found no effect on measured blood pressure (62) . Although the data are limited there appears to be no antihypertensive effects of these compounds in humans, neither is there any indication of adverse effects on blood pressure.
Polyphenols
It has been suggested that consumption of flavonoid-rich fruits and vegetables may lower blood pressure (63) . Studies on the influence of polyphenols on blood pressure are very diverse and have included a great variety of polyphenol-containing foods, including: grapes, berries, cocoa product, tea and other. Some studies have demonstrated a significant beneficial effect of grape-derived polyphenols on blood pressure (64, 65) . On the other hand, there also numerous studies which did not identify such an association (66, 67, 68) . The conflicting results probably result from the heterogeneity of study design, polyphenol source and population characteristics.
A recently published randomized controlled trial indicated that grape seed extract significantly reduced systolic blood pressure by 5.6% and diastolic blood pressure by 4.7% after 6 weeks of supplementation in subject with mildly elevated blood pressure. Moreover, the blood pressure lowering effects appeared to be dependent on baseline blood pressure, with the greatest reduction observed in subjects with higher baseline blood pressure (69) .
The effects of resveratrol on blood pressure have also been studied. A meta-analysis of 6 randomized controlled trials, (247 subjects), appeared to show a dose-response relationship only higher doses (≥150 mg day-1) of resveratrol significantly reduced systolic blood pressure while there were no significant effects on diastolic blood pressure (70) . Another meta-analysis, which included data from 10 randomized controlled trials indicated that resveratrol supplementation did not affect systolic and diastolic blood pressure (38) .
Differences in the baseline blood pressure of participants in the study may account for some of these discrepancies.
Cocoa flavanols are the most studied polyphenols in the clinical setting. A meta-analysis of 20 randomized controlled trials involving healthy participants indicated that consumption of polyphenol-rich cocoa products was associated with a reduction in blood pressure (71) . A meta-analysis of 42 randomized controlled trials indicated that chocolate or cocoa was associated with reduced diastolic blood pressure and mean arterial pressure (72) . Very recent clinical studies also confirm that cocoa flavanols exert a beneficial impact on blood pressure in patients with type 2 diabetes and hypertension (40) and in elderly subjects (73) . Moreover, a recent study has demonstrated similar findings after cocoa ingestion in healthy individuals (74) . This was associated with a dose-dependent improvement in flow-mediated dilation, decreased endothelin-1 and pulse wave velocity. These findings warrant further investigation into the potential uses for cocoa in the prevention of CVD (74) .
Conversely, another study found no evidence of an effect of daily intake of dark chocolate (49 g/day) on blood pressure or arterial stiffness in patients with mild hypertension (75) . The Flaviola Health Study found that cocoa flavanol intake (450 mg) for 1 month decreased systolic and diastolic blood pressure by 4.4 mmHg and 3.9 mmHg, pulse wave velocity by 0.4 m/s and led to improved endothelial function in a healthy, primary prevention population, suggesting potential benefits of cocoa in maintain cardiovascular health (45) .
Studies on tea polyphenols have also reported blood pressure lowering properties (48, 76) . A meta-analysis of 10 trials (834 participants) demonstrated that a statistically significant reduction in systolic blood pressure was associated with diastolic blood pressure with black or green tea consumption (77) . Furthermore, a recent meta-analysis on the effects of green tea intake on risk of cardiovascular disease indicated that consumption of green tea is associated with reduced risk of myocardial infarction and stroke (78) .
Several clinical studies have demonstrated an antihypertensive effect of pomegranate juice. A recent meta-analysis, which included the results of eight randomized controlled trials investigating the effects of pomegranate juice on blood pressure indicated that consumption of this polyphenol-rich juice significantly reduced both systolic and diastolic blood pressure (79) . In addition, lipid-lowering, antioxidant and anti-atherosclerotic actions of pomegranate juice have been reported, making it a very attractive candidate as a nutraceutical with the potential to improve cardiovascular health (80) .
The nutraceutical product, Armolipid Plus (containing red yeast rice, policosanol, berberine, folic acid, astaxanthin and coenzyme Q10) was found to be safe, well tolerated and effective in reducing mean 24-h systolic and 24-h pulse pressure in hypertensive and hypercholesterolemic subjects at low cardiovascular risk (51) .
Spirulina
Some studies indicated that Spirulina maxima might exert an antihypertensive effect. Oral Spirulina supplementation resulted in systolic and diastolic blood pressure reduction in a small clinical trial (55) . Conversely, no effect of Spirulina upon blood pressure was observed after consumption of 1 g Spirulina per day for 12 weeks in a Greek population (56) .
Administration of 2 g Hawaiian Spirulina for 3 months was associated with improved blood pressure and endothelial function in patients with hypertension. However, evidence relating to cardiovascular outcomes is lacking and further well-designed trials are required to clarify the clinical value of Spirulina supplementation in lowering blood pressure (81) . Table 1 summarizes the methodology and main findings from each study described in the paper.
DIABETES MELLITUS
Diabetes mellitus is a well-established risk factor for cardiovascular disease. Diabetes mellitus type 2 is associated with high risk for developing cardiovascular complications (82) .
Moreover, patients with diabetes and hypertension have about twice the risk of cardiovascular events as nondiabetic patients with hypertension (83) . It has been estimated that the global prevalence of diabetes mellitus will rise to 552 million by 2030 (84) . Observational studies indicated that diet is one of the factors, which might prevent diabetes and its complications (85) . The TOSCA observational study demonstrated that a diet characterized by a higher intake of total polyphenols was associated with a better cardiovascular risk factors profile and a lower grade of subclinical inflammation in population with diabetes mellitus type 2 (86) .
Polyphenols
Relatively few studies have evaluated the effects of grape polyphenol on hyperglycemia.
Guilford et al. (87) indicated that regular red wine consumption is associated with a 30% risk reduction for type 2 diabetes. Consumption of grape seed polyphenols and red wine grape pomace flour have been associated with significant reductions in blood glucose (88, 89) .
Conversely another study found no effect of grape juice polyphenols in healthy individuals (90) .
A randomized controlled trial revealed that supplementation of resveratrol for 3 months significantly improved the mean hemoglobin A1c, in patients with type 2 diabetes mellitus (91) . A recent meta-analysis of 11 randomized controlled trials found that resveratrol reduced fasting glucose, insulin, glycated hemoglobin, and insulin resistance in subjects with type 2 diabetes, but not in those without diabetes (92) . Conversely, a meta-analysis of 10 randomized controlled trials did not indicate a significant effect of resveratrol supplementation upon glucose level (38) . The mechanism of action of resveratrol in the treatment of diabetes mellitus seems to be multifactorial; resveratrol may have antioxidant properties, increase AMPK activation, and increase internalization of glucose through modulating glucose transporter expression (93, 94, 95) .
Results from studies evaluating influence of cocoa and tea polyphenols on glycemic markers are inconclusive. A meta-analysis of 42 randomized controlled trials indicated that chocolate or cocoa reduced fasting insulin concentrations, insulin after glucose challenge and improved insulin resistance. However, no effect upon fasting glucose or HbA1c was observed (72) .
Consumption of chocolate high in polyphenols was not associated with differences in fasting insulin in patients with diabetes mellitus type 2 and hypertension (40) .
Another study found an independent inverse relationship between daily chocolate intake and concentrations of insulin, homeostatic model assessment of insulin resistance (HOMA-IR) and liver enzymes. Results of that study suggest that chocolate intake result in beneficial changes in liver enzymes and protect against insulin resistance (96) . The results of a randomized controlled trial also support a role for cocoa flavanol intake in improving insulin resistance (44) . The current data is insufficient to recommend chocolate and cocoa for glycemic control.
A meta-analysis of 17 trials comprising a total of 1133 subjects revealed that green tea consumption was associated with significantly reduced fasting glucose and hemoglobin A1c (97) . Furthermore, a meta-analysis of has also indicated changes in fasting glucose but glycated hemoglobin similar as fasting blood insulin and HOMA-IR did not change after green tea catechins administration (98) . In a meta-analysis of 10 trials, which evaluated effect of green tea on populations at risk of diabetes mellitus type 2, green tea was not associated with reduced levels of fasting plasma glucose, fasting serum insulin, 2-h plasma glucose in the oral glucose tolerance test, hemoglobin A1c (HbA1c) and HOMA-IR (99) .
Recent meta-analysis of 10 trials including 608 subjects which aimed to indicate the effect of green tea in patients with diabetes mellitus type 2 found that tea could alleviate the decrease of fasting blood insulin and reduced waist circumference only when the intervention was extended for longer than 8-weeks. No effects of tea on HOMA-IR, fasting blood glucose, LDL-C, HDL-C, body mass index, systolic blood pressure, diastolic blood pressure, triglycerides and fasting cholesterol were observed (100). These mixed results mean that it is unclear whether green tea has anti-diabetic effects.
Polyphenols might influence glucose homeostasis by several mechanisms, by inhibiting carbohydrate digestion and glucose absorption in the intestine, protecting pancreatic -cells, reducing glucose release from liver and activating insulin receptors and glucose uptake in insulin-sensitive tissues (101) .
Spirulina
Spirulina might be beneficial in controlling blood glucose level in subject with diabetes mellitus type 2. Supplementation of 2 g/day for 2 months resulted in reduced fasting blood glucose, postprandial blood glucose levels and HbA1c (53) . Conversely oral supplementation of Spirulina in a separate trial (4.5 g/day, for 6 weeks) did not result in changes in the markers of glucose metabolism (55) . Further trials are required to clarify the clinical value of Spirulina supplementation in treatment of diabetes. Table 1 summarizes the methodology and main findings from each study described in the paper. Reduction in BMI, weight, SBP and stiffness index *Abbreviations: PWV -pulse wave velocity, MI --myocardial infarction, ApoAI -apolipoprotein AI, ApoBapolipoprotein B, Hcy -homocysteine, FBS -fasting blood sugar, HbA1c -hemoglobin A1c, HOMA-IRhomeostasis model assessment-insulin resistance, CHF -congestive heart failure, HT -hypertension, HChhypercholesterolemia, FBG -fasting blood glucose, FBI -fasting blood insulin.
